AI-Generated Summary

New Phase 2 clinical trial results from UCLA Health demonstrate that adding a PSMA-targeted radioligand therapy (177Lu-PNT2002) to stereotactic body radiotherapy (SBRT) more than doubles progression-free survival in patients with recurrent prostate cancer. This combination extended median progression-free survival to 17.6 months compared to 7.4 months with SBRT alone, significantly delaying the need for hormonal therapy. The findings suggest an earlier role for radioligand therapy in managing oligorecurrent prostate cancer with minimal additional side effects.

In a nutshell

This trial represents a crucial proof-of-principle for earlier intervention with radioligand therapy, potentially transforming the treatment paradigm for oligorecurrent prostate cancer. By delaying the need for hormone therapy and leveraging advanced theranostics, it offers a pathway to improved patient quality of life and enhanced disease control.

Source: Medical Xpress